Bromhexine tablets 8mg, No. 20

• Diseases of the respiratory tract, accompanied by difficulty in the discharge of viscous sputum: tracheobronchitis, bronchitis of various etiologies (including those complicated by bronchiectasis), bronchial asthma, pulmonary tuberculosis, pneumonia, cystic fibrosis.

• Rehabilitation of the bronchial tree in the preoperative period and during medical and diagnostic intrabronchial manipulations, prevention of the accumulation of thick viscous sputum in the bronchi after surgery.

Bromhexine is taken orally, regardless of food intake. Adults are prescribed 8-16 mg 3-4 times a day; children from 6 to 14 years old - 8 mg 3 times a day.

The course of treatment is from 4 to 28 days.

In the course of treatment, it is recommended to consume a sufficient amount of liquid, which supports the secretolytic effect of bromhexine.

1 tablet contains

The active ingredient is bromhexine hydrochloride - 8 mg.

Excipients: potato starch, lactose (milk sugar), sucrose (sugar), calcium stearate.

• Hypersensitivity to the components of the drug;

• lactation period;

• pregnancy (I trimester);

• peptic ulcer (in the acute stage);

• children under 6 years of age.

  Carefully

• History of gastrointestinal bleeding, renal and / or hepatic failure, bronchial diseases, accompanied by excessive accumulation of secretions.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Mucolytic (secretolytic) agent, has an expectorant and weak antitussive effect. Reduces the viscosity of sputum (depolymerizes mucoprotein and mucopolysaccharide fibers, increases the serous component of bronchial secretions); activates ciliated epithelium, increases volume and improves sputum discharge. Stimulates the production of endogenous surfactant, which ensures the stability of alveolar cells during respiration. The effect appears within 2-5 days from the start of treatment.

Pharmacokinetics

When taken orally, bromhexine is almost completely (99%) absorbed in the gastrointestinal tract within 30 minutes. Bioavailability - low (the effect of primary 'passing' through the liver). Penetrates the blood-brain and placental barriers. In the liver, bromhexine undergoes demethylation and oxidation, and is metabolized to the pharmacologically active ambroxol. The half-life is 15 hours (due to slow reverse diffusion from tissues). It is excreted by the kidneys. In chronic renal failure, the excretion of metabolites is impaired. With repeated use, bromhexine can accumulate.

SIDE EFFECT

Allergic reactions, dyspepsia, incl. nausea, vomiting; exacerbation of gastric ulcer and 12 duodenal ulcer, dizziness, headache, increased activity of 'hepatic' transaminases.

Overdose

Symptoms: nausea, vomiting, diarrhea.

Treatment: symptomatic, gastric lavage (in the first 1-2 hours after ingestion).

Interaction

Bromhexine can be administered concurrently with other drugs used in the treatment of bronchopulmonary diseases.

Bromhexine is not prescribed concurrently with drugs containing codeine, as this makes it difficult to cough up liquefied sputum.

Bromhexine promotes the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.

Bromhexine is incompatible with alkaline solutions.

special instructions

During treatment, it is necessary to take a sufficient amount of liquid, which increases the expectorant effect of bromhexine.

In children, treatment should be combined with postural drainage or vibration massage of the chest, facilitating the removal of secretions from the bronchi.